Home Cart Sign in  
Chemical Structure| 1338806-73-7 Chemical Structure| 1338806-73-7

Structure of CFI-400945
CAS No.: 1338806-73-7

Chemical Structure| 1338806-73-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CFI400945 is a potent and selective,orally bioavailable PLK4 inhibitor with an IC50 value of 2.8 ±1.4 nM have potential antineoplastic activity.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CFI-400945

CAS No. :1338806-73-7
Formula : C33H34N4O3
M.W : 534.65
SMILES Code : O=C([C@@]12[C@H](C3=CC4=C(C=C3)C(/C=C/C5=CC=C(CN6C[C@@H](C)O[C@@H](C)C6)C=C5)=NN4)C1)NC7=C2C=C(OC)C=C7
MDL No. :MFCD28386170
InChI Key :DADASRPKWOGKCU-FVTQAUBDSA-N
Pubchem ID :58486178

Safety of CFI-400945

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • PLK4

    PLK4, IC50:2.8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SK-UT-1 22.8 ± 6.0 nmol/L 6 days CFI-400945 demonstrated dose-dependent antitumor activity with an IC50 of 22.8 ± 6.0 nmol/L. PMC11369621
SKN 35.5 ± 12.0 nmol/L 6 days CFI-400945 demonstrated dose-dependent antitumor activity with an IC50 of 35.5 ± 12.0 nmol/L. PMC11369621
SK-LMS-1 52.72 ± 13.1 nmol/L 6 days CFI-400945 demonstrated dose-dependent antitumor activity with an IC50 of 52.72 ± 13.1 nmol/L. PMC11369621
DLBCL cell line LY8 20 nM or higher 48 hours To evaluate the effects of CFI-400945 on DLBCL cell apoptosis, results showed that CFI-400945 significantly induced apoptosis PMC8222327
ED1 cells 20 nM or higher induced apoptosis PMC10682029
LKR13 cells 20 nM or higher induced apoptosis PMC10682029
393P cells 20 nM or higher induced apoptosis PMC10682029
H1299 cells 20 nM or higher induced apoptosis PMC10682029
Hop62 cells 20 nM or higher induced apoptosis PMC10682029
A549 cells 20 nM or higher induced apoptosis PMC10682029

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c nude mice SK-UT-1 xenograft model Oral 0.5 mg/kg Once daily for 2 weeks CFI-400945 demonstrated dose-dependent antitumor activity in vivo, with both low-dose (5 mg/kg) and high-dose (7.5 mg/kg) significantly reducing tumor volume. PMC11369621
SCID/Beige mice DLBCL xenograft model oral 5 mg/kg and 7.5 mg/kg Once daily for 3 weeks To evaluate the anti-tumor effects of CFI-400945 in combination with doxorubicin in DLBCL xenograft models, results showed that the combination therapy significantly suppressed tumor growth and delayed tumor progression PMC8222327
mice lung cancer xenograft model oral 0.5 mg/kg Twice a week for three weeks significantly inhibited lung tumor growth PMC5828621
C57BL/6J mice Complete carotid ligation model Local administration (via hydrogel) 7.5 mg/kg once daily for 21 days CFI-400945 significantly inhibited neointima formation in carotid arteries. PMC9905587

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01954316 Advanced Cancer PHASE1 COMPLETED 2021-07-22 UCLA Medical Center, Santa Mon... More >>ica, California, 90404, United States|Princess Margaret Cancer Centre, Toronto, Ontario, M5G 2M9, Canada Less <<
NCT03624543 Breast Cancer PHASE2 ACTIVE_NOT_RECRUITING 2025-12-31 Juravinski Cancer Centre at Ha... More >>milton Health Sciences, Hamilton, Ontario, L8V 5C2, Canada|London Regional Cancer Program, London, Ontario, N6A 5W9, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, K1H 8L6, Canada|Odette Cancer Centre, Toronto, Ontario, M4N 3M5, Canada|University Health Network, Toronto, Ontario, M5G 2M9, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, S4T 7T1, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.35mL

1.87mL

0.94mL

18.70mL

3.74mL

1.87mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories